Coronavirus Breaking News

The coronavirus disease COVID-19 is currently reaching pandemic levels in various countries.

May 9, 2025 • 8:28 am CDT
Google Maps May 9, 2025

Since the first anthrax fatality in decades was reported in the Kingdom of Thailand in early May 2025, substantial confusion regarding a potential outbreak has been reported on social media.

To clarify the situation as of May 8, 2025, Dr. Pricha Worahan, Public Health Doctor of Nakhon Phanom Province, revealed that the anthrax situation in Mukdahan Province has been continuously monitored.

As for the latest disease situation, there are no confirmed anthrax patients. Anthrax is a zoonotic disease caused by the bacterium Bacillus anthracis.

There was one suspected anthrax patient found, a 55-year-old female farmer who denied any underlying diseases. She had a blister on her right arm that broke in the middle, making the wound black like a cigarette burn.

The doctor initially diagnosed anthrax as suspected, so he collected samples of the blister from her skin and Hemoculture to send to the laboratory of Nakhon Phanom Hospital and Bamrasnaradura Institute. No one with symptoms that fit the definition of searching for contacts of the disease was found.

However, two people who had contact with the infected person did not show any symptoms, and animals in the area did not show any abnormalities or die of unknown causes.

There are no reports of human-to-human transmission of the disease.

The most common vectors are cows, buffalo, goats, and sheep. Infected animals will have fever, be lethargic, not eat, get sick for no apparent reason, and die. Most people get infected by direct contact with infected animals, such as butchering meat, consuming raw or undercooked meat, or coming into contact with animal skins or fur that contain spores of the disease.

The germs contaminate the area where an animal is sick or dies and can remain there for months or years. Patients will have fever, body aches, cough, difficulty breathing, a blue face, and die from respiratory failure.

According to the U.S. CDC, anthrax is rare in the United States, but outbreaks do happen in wild and domestic grazing animals such as cattle or deer. In the U.S., veterinarians recommend yearly livestock vaccination in areas where animals have had anthrax. Additionally, anthrax vaccines for people are available in 2025.

Recently, South Korea approved BARYTHRAX, the world's first recombinant anthrax vaccine, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency.

BARYTHRAX utilizes protective antigen (PA) proteins produced through genetic recombination techniques. With an anthrax infection, PA is a gateway for 2 Bacillus anthracis toxins, lethal factor and edema factor, to enter host cells. BARYTHRAX vaccination can train and stimulate an immune response to neutralize anthrax by utilizing PA proteins.

May 9, 2025 • 5:47 am CDT
by Marcela P.

With about 8 million cases annually, gonorrhea is one of the most common sexually transmitted infections, without a U.S. FDA-approved vaccine available.

However, another study has concluded that leveraging an existing vaccine provides some cross-protection against N. gonorrhoeae.

Published by the journal Vaccine (Volume 56, 22 May 2025, 127180), this study evaluates the potential effectiveness of outer membrane vesicle (OMV)-based meningococcal B vaccines in preventing this sexually transmitted infection.

A recent review and meta-analysis, which included nine studies, found a pooled vaccine effectiveness of 30% when a 4CMenB vaccine was administered.

The University of West Attica researchers concluded, "While randomized clinical trials are necessary, the findings of this systematic review and meta-analysis highlight the potential effectiveness of OMV-based vaccines in preventing gonorrhea."

This new research, along with previous studies, suggests that the four-component serogroup B meningococcal vaccine (4CMenB) and other OMV-based MenB vaccines might offer such protection against this disease.

4CMenB vaccinations are offered at many community pharmacies in the United States in 2025.

May 8, 2025 • 11:12 am CDT
Google Maps May 8, 2025

With millions of people planning to visit the Republic of the Philippines during the summer of 2025, the United States government has recently updated various travel advisories.

On May 8, 2025, the Department of State reissued its Level 2: Exercise Increased Caution due to civil unrest in some areas of the Philippines. This advisory says do not travel to:

The Sulu Archipelago, including the southern Sulu Sea and Marawi City in Mindanao,

And reconsider visiting other areas of Mindanao this year.

Due to these risks, the State Department wrote that U.S. government employees working in the Philippines must obtain special authorization to travel to these areas.

If you visit the Philippines in 2025, enroll in the Smart Traveler Enrollment Program to receive digital alerts and help locate you in an emergency.

Last month, the U.S. Embassy Manila announced 'Beat the Summer Rush – Renew Your Passport Today.'

Appointments for routine consular services are currently available with little to no wait at the U.S. Embassy and the Consular Agency in Cebu.  As summer approaches, demand will rise, making it harder to schedule convenient times. Apply now to avoid the busy season!

From a health risk perspective, the Centers for Disease Control and Prevention (CDC) has included the Philippines in two Travel Health Advisories in 2025.

The CDC's dengue advisory was issued in April, and a global measles advisory was issued in March.

While dengue vaccines are unavailable in the U.S., MMR vaccines are readily offered at travel clinics and pharmacies.

Furthermore, the CDC says international travelers should check the list of routine vaccines and medicines and visit a healthcare provider at least a month before departing abroad this summer.

May 8, 2025 • 6:30 am CDT
Takeda May 8, 2025

According to the World Health Organization (WHO), more than 13 million dengue cases were reported in 2024, the highest number on record.

According to recent data, the dengue global outbreak has continued in 2025.

To reduce the health impact of this mosquito-transmitted viral infection, more people than ever were immunized with a dengue vaccine.

Announced today by Japan-based Takeda, the only WHO-listed dengue vaccine QDENGA®'s Q4 FY2024 (April 2024-March 2025), Revenue was JPY 35.6 billion ($247,746,985), an increase of 259%.

QDENGA® (TAK-003) is a tetravalent, two-dose vaccine approved for preventing dengue fever and/or Severe Dengue caused by any of the four serotypes of the dengue virus. 

As of May 8, 2025, QDENGA was authorized in about 40 countries, with authorizations pending in the Philippines and India. 

Unfortunately, no dengue vaccine is available in the United States, even in Puerto Rico, were dengue has become endemic.

May 6, 2025 • 5:10 pm CDT
from Pixabay 2025

A large-scale, population-based cohort study with a long-term follow-up recently investigated the association between live zoster (shingles) vaccination and the risk of various cardiovascular events.

A study published in the European Heart Journal on May 5, 2025, found a 23% lower risk of cardiovascular events in recipients of the shingles vaccine in the eight years following vaccination, with the most significant reduction observed 2–3 years post-vaccination.

The decrease in cardiovascular disease risk was more pronounced among males, individuals aged less than 60 years, those with unhealthy lifestyle habits, and those from low-income households and rural residents.

"A shingles infection can cause blood vessel damage, inflammation, and clot formation that can lead to heart disease," said study author Dong Keon Yon, PhD, from the Kyung Hee University College of Medicine, Seoul, in a press release.

"By preventing shingles, vaccination may lower these risks."

These findings suggest that live zoster vaccination may be beneficial for reducing the burden of cardiovascular disease in the general population.

May 6, 2025 • 1:40 pm CDT
ARS Regional Health Agency May 2, 2025

France's ARS Regional Health Agency continues to report chikungunya fever outbreaks in its Departments located east of Africa and Madagascar.

According to the information bulletin released by the Regional Health Agency on May 2, 2025, there have been 89 recorded cases in the Mayotte Department, a significant increase from 32 cases confirmed just two weeks ago.

Mayotte's outbreak breakdown includes 28 imported cases, 28 indigenous cases, and 33 cases currently under investigation. Additionally, two patients have been hospitalized.

The Regional Health Agency indicates that this health risk to the general population and any international visitors is high, and the outbreak could continue for weeks.

Since chikungunya is a vaccine-preventable disease, health authorities announced last week that adults aged 65 and younger will be included in the vaccination campaign in Mayotte.

A recent study found that a disease-blocking vaccine with 75% efficacy, if administered to 40% of individuals aged 12 years and older over three months, could have prevented approximately 34,200 chikungunya cases and 73 related fatalities.

In addition to chikungunya, Mayotte's cholera transmission are localized to Koungou, M'tsangamouji, and Mamoudzou. Mayotte increased its use of the cholera vaccine DUKORAL in the first quarter of 2025.

As of May 6, 2025, the U.S. CDC has not issued a Travel Health Advisory for visiting Mayotte.

 

May 6, 2025 • 12:38 pm CDT
US CDC 2025

The Los Angeles County Department of Public Health (LAC DPH) has declared a communitywide outbreak of hepatitis A virus (HAV), a vaccine-preventable disease.

Since January 2024, 167 cases have been confirmed in LAC residents, including 29 in 2025. Typically, 30-50 cases are confirmed per year.

According to the U.S. CDC., the number of estimated new HAV infections increased annually in the U.S. beginning in 2015, peaked in 2019, and sharply decreased in 2020. This downward trend continued through 2023, reaching 3,300 estimated infections.

As of May 5, 2025, most LAC hepatitis A cases have occurred in people without typical risk factors such as travel, unstable housing, or illicit drug use.

Hepatitis A vaccine is widely available at primary care provider offices, pharmacies, and participating community sites serving uninsured people. It is also available at no cost at LAC DPH clinics. And private health insurance plans should cover the hepatitis A vaccine at no cost to beneficiaries.

May 6, 2025 • 9:02 am CDT
by Gerd Altmann

While human-to-human transmission of avian influenza remains low, highly pathogenic strains such as H5N1 and H7N9 continue to pose serious global threats. According to the World Health Organization (WHO), if H5N1 mutates to enable human-to-human transmission, it could trigger a deadly pandemic.

Various avian influenza vaccines have been developed, and new, innovative technologies are being tested to address this global threat.

SK bioscience today announced that it has been selected for the Korea Disease Control and Prevention Agency (KDCA)- led initiative to develop vaccines against avian influenza, which has been identified as a high-risk candidate for the next pandemic.

Under the new program, SK bioscience and KDCA will co-invest approximately $3.7 million in early-stage development.

The company stated on May 6, 2025, that it will initiate development of a cell-culture-based avian influenza vaccine and aim to enter Phase 1/2 clinical trials in the second half of 2026.

The company says cell-culture-based vaccines offer greater effectiveness in pandemic response than traditional egg-based vaccines. Egg-based vaccines can face significant challenges during avian influenza outbreaks, as mass culling of poultry may limit access to uninfected fertilized eggs, making timely and large-scale vaccine production difficult and less responsive to emerging viral mutations.

In contrast, cell-culture-based vaccines are produced using animal cells in advanced aseptic facilities, minimizing the risk of contamination or infection. This method enables rapid, large-scale manufacturing and quicker adaptation to evolving virus strains.

SK bioscience has already utilized its cell-culture platform to develop vaccines against various viral diseases.

In the United States, various avian influenza vaccines have been supported by the U.S. FDA over the past few years.

May 5, 2025 • 3:53 pm CDT
EU May 2025

The Brussels-based European Union (EU) and France today announced $566.6 million worth of incentives to lure scientists to the continent.

According to local media on May 5, 2025, the funds will support research projects and help universities cover the cost of recruiting foreign scientists.

"We call on researchers worldwide to unite and join us," French President Emmanuel Macron said at Paris' Sorbonne University alongside European Commission President Ursula von der Leyen.

The EU's President Von der Leyen also wants its member states to invest 3% of their gross domestic product in research and development by 2030.

May 5, 2025 • 1:07 pm CDT
by Sonja Czeschka

As the summer vacation season 2025 gets underway, the U.S. Centers for Disease Control and Prevention (CDC) cruise ship illness inspections are on pace to set new, unfortunate records.

As of May 5, 2025, the CDC's Vessel Sanitation Program had reported 16 gastrointestinal (GI) illnesses on cruise ships this year, 14 of which were classified as norovirus.

This data compares with 18 GI outbreaks in all of 2024 and just 14 in 2023.

The CDC says traveling on cruise ships exposes people to new environments and thousands of other voyagers. Health risks come from contaminated food or water or, more commonly, through person-to-person contact and a lack of hand-washing.

The most recent report was from the cruise ship Eurodam. As of April 28, 2025, the final case counts were:

Number of passengers who reported being ill during the voyage: 148 of 2,038 (7.26%),

Number of crew who reported being ill during the journey: 22 of 830 (2.65%),

The predominant symptoms were diarrhea, vomiting, and abdominal cramps, and the causative agent was norovirus.

The CDC offers this quick tip to help about 20 million people vacationing on a North American cruise ship in 2025: To avoid getting sick, wash your hands often, especially after visiting a public bathroom and before/after eating a group-served meal.

With Disney soon to cruise to the western Caribbean from Galveston, Texas, more people should follow this CDC advice for the years ahead.

While norovirus vaccine candidates are being tested in clinical research to help prevent outbreaks, none are available in 2025.

May 5, 2025 • 11:51 am CDT
Pixabay 2025

Over the past Respiratory syncytial virus (RSV) seasons, infants have been offered a new monoclonal antibody to protect them from lower respiratory tract infections (LRTIs).

A cost-effectiveness analysis, published on May 3, 2025, estimates the economic benefits.

From the NHS perspective, over the first RSV season, Beyfortus™ (nirsevimab) in an all-infants population could be a cost-effective approach to preventing LRTIs.

These researchers concluded that a prophylaxis strategy against RSV infection targeting all infants with Beyfortus could represent a cost-effective option and support the implementation and equity of RSV prevention for all infants.

For the 2025-2026 RSV season in the United States, Beyfortus is FDA-approved and readily available.

May 5, 2025 • 9:12 am CDT
by Pete Linforth

The only protein-based, non-mRNA COVID-19 vaccine produced in the United States will continue to be available in Japan, the world's third-largest pharmaceutical market.

Novavax, Inc., announced on May 5, 2025, that it has updated the terms of the previously announced collaboration and licensing agreement with Takeda, a pharmaceutical firm located in Osaka, Japan.

"Our ongoing partnership with Takeda is important for Novavax, and our strengthened agreement enhances our ability to operate effectively in the Japanese market," said John C. Jacobs, President and CEO of Novavax, in a press release.

"This partnership further validates our cutting-edge technology platform and proprietary Matrix-M® adjuvant and our efforts to become a partner of choice."

The improved financial terms of the amended agreement for the development, manufacturing, and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 season, annual milestones associated with regulatory approvals, and royalties on net sales earned every season moving forward.

Since the World Health Organization granted an Emergency Use Listing for Novavax's earlier COVID-19 vaccine version in December 2021, numerous countries, including the United States, have authorized its use.

Novavax's vaccines are genetically engineered using three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis.

May 4, 2025 • 1:28 pm CDT
Canada Health May 4, 2025

A multijurisdictional measles outbreak is ongoing in Canada and the United States in 2025.

Although measles was eliminated in Canada in 1998, an average of 91 cases, many travel-related, were reported annually.

According to the Canadian Government's data release on May 2, 2025, the current outbreak began in New Brunswick in October 2024 and has continued to spread in Alberta, Manitoba, Ontario, Prince Edward Island, and Quebec.

The data revealed 970 measles cases had been reported in Ontario, out of the 1,177 total cases in Canada. Of the virus genotypes analyzed, D8 was dominant.

During Ontario's outbreak, 451 measles cases have been confirmed in Ontario's Southwestern Public Health, including the City of St. Thomas, Elgin County, and Oxford County.

Data from Toronto, a city with over 2.7 million people, has confirmed only three cases.

These data indicate that Ontario's measles outbreak is primarily a rural, not urban, concern.

As of May 1, 2025, the Centers for Disease Control and Prevention (CDC) reported 935 confirmed measles cases in 30 U.S. jurisdictions, with Texas the leader.

Measles is an exceptionally infectious virus but can be easily prevented with an effective vaccine.

A study published by The Lancet in May 2025 supports using the MR vaccine at six months to protect young infants during measles outbreaks and in settings with increased risk or high transmission.

The CDC recommends evaluating your family's need for early vaccine doses before international travel. After you return, monitor your health for three weeks and call your healthcare provider if you or your child gets sick with a rash and fever.

May 4, 2025 • 4:55 am CDT
US CDC May 2025

The Republic of Indonesia's tourism sector experienced significant growth in 2024, with foreign tourist arrivals increasing by 20% compared to the same period in 2023.

However, the U.S. Department of State recently issued a high-level advisory for international visitors to consider before visiting Indonesia in 2025.

On April 30, 2025, the U.S. Department of State advised visitors to exercise increased caution in Indonesia due to civil unrest.

Especially when visiting Central Papua and Highland Papua.

The Level 4, Do Not Travel advisory says that in Central Papua and Highland Papua, violent demonstrations and conflict could result in injury to U.S. citizens and foreign nationals. Due to the risks, the U.S. government cannot provide emergency services to U.S. citizens in Central Papua and Highland Papua.

Seperately, the U.S. CDC includes Indonesia in recent measles and polio travel advisories.

Additionally, there has been recent evidence of the transmission of the chikungunya, dengue, and Japanese encephalitis viruses in Indonesia.

The CDC recommends that everyone visiting Indonesia be up to date with routine vaccinations and consult with a vaccine expert to determine which travel vaccines are best suited for their visit.

May 3, 2025 • 6:00 am CDT
from Pixabay 2025

The UK Health Security Agency (UKHSA) recently reviewed its guidance for countries at risk of dengue fever outbreaks. Last year, records of dengue outbreaks and related fatalities were set in many countries.

As of May 2, 2025, based on this review, most countries with a known risk of dengue now have a vaccine recommendation for some travellers.

However, the following countries have sporadic local dengue cases, but a vaccine is not recommended: Australia, Croatia, France, Italy, Madeira, Spain, the United Arab Emirates, and the United States.

In the U.S., locally acquired dengue was reported in 2025 in areas such as Miami-Dade County in Florida.

According to the UKHSA, health professionals should consider the possibility of dengue in all returned UK travellers with a fever or flu-like illness who have recently visited dengue risk regions. Suspected dengue patients should discuss this matter with their local microbiology, virology, or infectious diseases consultant, giving a full travel/clinical history. 

The live, attenuated dengue vaccine called Qdenga® is licensed in the UK, but is unsuitable for all travellers.

Qdenga is currently not licensed in the U.S.

The UKHSA and NaTHNaC dengue recommendations are based on published data focusing on evidence of local mosquito-borne dengue transmission from January 2020 to December 2024.